Skip to main content
. 2022 Apr 27;13:807466. doi: 10.3389/fgene.2022.807466

TABLE 4.

Pooled results on the association between the TP53 IVS6+62A > G (rs1625895) polymorphism and BC risk.

Variable n (Cases/Controls) CG vs. CC GG vs. CC GG + CG vs. CC GG vs. CC + CG G vs. C
OR (95%CI) P h/I 2 (%) BFDP OR (95%CI) P h/I 2 (%) BFDP OR (95%CI) P h/I 2 (%) BFDP OR (95%CI) P h/I 2 (%) BFDP OR (95%CI) P h/I 2 (%) BFDP
Overall 25 (12,222/12,895) 1.01 (0.89, 1.14) a <0.001/61.6 0.93 (0.79, 1.11) 0.180/20.4 1.00 (0.89, 1.14) a <0.001/65.0 0.95 (0.81, 1.12) 0.542/0.0 1.00 (0.90, 1.11) a <0.001/62.7
Matching
 No/NR 12 (5,551/5,024) 0.91 (0.72, 1.14) a <0.001/73.7 0.84 (0.55, 1.29) a 0.045/45.0 <0.001/75.6 0.96 (0.76, 1.22) 0.267/18.0 0.92 (0.77, 1.10) a <0.001/73.0
 Yes (include Age) 13 (6,671/7,871) 1.06 (0.98, 1.15) 0.139/30.6 0.96 (0.76, 1.21) 0.604/0.0 1.08 (0.95, 1.23) a 0.057/41.7 0.94 (0.75, 1.19) 0.689/0.0 1.06 (0.94, 1.20) a 0.043/44.2
Blinding and/or quality control
 No 14 (2,908/2,658) 0.87 (0.64, 1.18) a <0.001/71.4 0.80 (0.49, 1.31) a 0.085/36.4 0.86 (0.63, 1.17) a <0.001/74.1 0.90 (0.67, 1.22) 0.381/6.4 0.89 (0.70, 1.13) a <0.001/71.8
 Yes 11 (9,314/10,237) 1.03 (0.96, 1.11) 0.104/36.9 0.98 (0.80, 1.20) 0.514/0.0 1.05 (0.95, 1.16) a 0.078/40.7 0.97 (0.80, 1.19) 0.565/0.0 1.04 (0.95, 1.14) a 0.078/40.6
HWE
 In violation 4 (4,624/6,185) 1.03 (0.94, 1.14) 0.128/47.3 0.79 (0.59, 1.05) 0.869/0.0 1.01 (0.92, 1.11) 0.115/49.4 0.79 (0.59, 1.05) 0.890/0.0 0.99 (0.91, 1.08) 0.131/46.7
 Compliant 21 (7,598/6,710) 1.00 (0.85, 1.18) a <0.001/64.6 1.02 (0.83, 1.26) 0.123/27.1 1.00 (0.85, 1.18) a <0.001/68.0 1.05 (0.86, 1.29) 0.482/0.0 1.00 (0.87, 1.15) a <0.001/65.9
Source of control
 PB 13 (6,801/6,958) 1.06 (0.92, 1.21) a 0.044/44.2 0.90 (0.72, 1.13) 0.725/0.0 1.05 (0.91, 1.21) a 0.028/47.7 0.92 (0.74, 1.14) 0.783/0.0 1.02 (0.91, 1.15) a 0.051/42.7
 BV 4 (1,882/1,692) 1.04 (0.73, 1.46) a 0.011/73.1 1.74 (1.05, 2.91) 0.549/0.0 0.997 1.07 (0.76, 1.51) a 0.009/74.1 1.73 (1.04, 2.88) 0.598/0.0 0.997 1.08 (0.80, 1.46) a 0.013/72.2
 HB 3 (2,871/3,583) <0.001/92.0 0.010/78.1 <0.001/93.2 0.75 (0.52, 1.08) 0.154/46.5 <0.001/92.8
 NR 5 (668/662) 1.09 (0.83, 1.41) 0.424/0.0 1.08 (0.59, 1.99) 0.670/0.0 1.08 (0.84, 1.39) 0.454/0.0 1.03 (0.57, 1.88) 0.669/0.0 1.06 (0.85, 1.32) 0.531/0.0
Ethnicity
 African 1 (16/30) 3.25 (0.75, 14.02) 0.71 (0.03, 18.60) 2.89 (0.68, 12.35) 0.35 (0.02, 7.64) 1.37 (0.56, 3.32)
 Asian 1 (83/268) 1.02 (0.44, 2.37) 0.46 (0.02, 8.91) 0.91 (0.40, 2.09) 0.45 (0.02, 8.88) 0.83 (0.37, 1.83)
 Caucasian 19 (10,552/11,861) 1.01 (0.88, 1.15) a <0.001/68.0 0.94 (0.70, 1.25) a 0.051/37.4 1.00 (0.87, 1.15) a <0.001/71.4 0.94 (0.78, 1.13) 0.253/16.5 1.00 (0.88, 1.12) a <0.001/70.8
 Indian 3 (993/346) 0.99 (0.70, 1.40) 0.144/48.5 0.96 (0.49, 1.89) 0.604/0.0 1.01 (0.73, 1.40) 0.187/40.3 1.07 (0.66, 1.75) 0.933/0.0 1.02 (0.80, 1.32) 0.390/0.0
 Mixed 1 (578/390) 1.05 (0.78, 1.41) 1.07 (0.46, 2.49) 1.05 (0.79, 1.40) 1.05 (0.45, 2.45) 1.05 (0.81, 1.35)
Geographic region
 Asia 9 (1,528/1,057) 0.76 (0.48, 1.22) a <0.001/72.8 0.71 (0.47, 1.06) 0.141/34.6 <0.001/75.1 0.84 (0.59, 1.20) 0.578/0.0 0.82 (0.59, 1.15) a <0.001/71.6
 Europe 11 (8,369/9,417) 1.05 (0.94, 1.18) a 0.036/48.3 1.05 (0.84, 1.30) 0.305/14.6 1.05 (0.94, 1.18) a 0.035/48.5 1.04 (0.83, 1.29) 0.326/12.4 1.05 (0.95, 1.16) a 0.045/46.3
 North America 5 (2,325/2,421) 1.09 (0.75, 1.58) a 0.023/64.7 0.85 (0.58, 1.23) 0.447/0.0 1.09 (0.74, 1.62) a 0.010/70.1 0.85 (0.59, 1.24) 0.508/0.0 1.06 (0.76, 1.49) a 0.010/69.7
ER status
 Negative 2 (121/300) 0.72 (0.39, 1.32) 3.59 (0.32, 40.14) 0.78 (0.43, 1.41) 8.60 (2.97, 24.91) 0.430/0.0 0.961 0.87 (0.51, 1.49)
 Positive 2 (243/300) 1.23 (0.78, 1.94) 3.13 (0.32, 30.42) 1.27 (0.81, 2.00) 10.32 (4.31, 24.72) 0.224/32.4 0.265 1.27 (0.84, 1.92)
Tumor grade
 Grade I 2 (79/796) 1.23 (0.65, 2.31) 0.71 (0.09, 5.46) 1.17 (0.63, 2.17) 0.009/85.5 1.10 (0.63, 1.90)
 Grade II 2 (95/796) 0.92 (0.48, 1.78) 0.30 (0.02, 5.04) 0.82 (0.42, 1.58) 0.002/89.4 0.74 (0.40, 1.38)
 Grade III 2 (80/796) 0.94 (0.47, 1.88) 0.69 (0.09, 5.33) 0.92 (0.47, 1.78) 0.025/80.1 0.90 (0.49, 1.64)
Menopausal status
Postmenopausal 3 (382/240) 0.65 (0.30, 1.41) a 0.139/54.3 0.98 (0.19, 5.15) 0.833/0.0 0.68 (0.33, 1.39) a 0.156/50.3 3.27 (0.47, 22.62) a 0.035/70.2 0.79 (0.52, 1.19) 0.219/33.9
Premenopausal 3 (201/270) 1.20 (0.72, 2.01) 0.631/0.0 3.00 (0.59, 15.30) 0.624/0.0 1.30 (0.79, 2.15) 0.678/0.0 7.30 (1.54, 34.58) a 0.134/50.3 0.998 1.36 (0.87, 2.14) 0.730/0.0
Age
 <50 years 2 (513/528) 0.57 (0.41, 0.78) 0.924 0.62 (0.26, 1.53) 0.58 (0.42, 0.78) 0.900 <0.001/95.0 0.62 (0.47, 0.82) 0.954
 ≥50 years 2 (1058/961) 1.02 (0.82, 1.27) 1.05 (0.57, 1.94) 1.02 (0.82, 1.26) <0.001/95.1 1.02 (0.84, 1.23)
Sensitivity analysis
 Overall 6 (4,341/3,983) 1.01 (0.91, 1.11) 0.338/12.0 1.07 (0.79, 1.44) 0.580/0.0 1.01 (0.92, 1.12) 0.282/20.1 1.07 (0.80, 1.44) 0.625/0.0 1.01 (0.93, 1.11) 0.268/22.1
Ethnicity
 Caucasian 5 (3,763/3,593) 1.00 (0.90, 1.11) 0.233/28.4 1.07 (0.78, 1.47) 0.435/0.0 1.00 (0.90, 1.12) 0.187/35.2 1.07 (0.78, 1.47) 0.480/0.0 1.01 (0.92, 1.11) 0.174/37.0
 Mixed 1 (578/390) 1.05 (0.78, 1.41) 1.07 (0.46, 2.49) 1.05 (0.79, 1.40) 1.05 (0.45, 2.45) 1.05 (0.81, 1.35)
Geographic region
 Europe 5 (3,763/3,593) 1.00 (0.90, 1.11) 0.233/28.4 1.07 (0.78, 1.47) 0.435/0.0 1.00 (0.90, 1.12) 0.187/35.2 1.07 (0.78, 1.47) 0.480/0.0 1.01 (0.92, 1.11) 0.174/37.0
 North America 1 (578/390) 1.05 (0.78, 1.41) 1.07 (0.46, 2.49) 1.05 (0.79, 1.40) 1.05 (0.45, 2.45) 1.05 (0.81, 1.35)
a

Random-effects model was used in the pooled data.

Note: The bold values indicate significant results.